Cardinal Health (NYSE:CAH – Get Free Report) was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Friday.
Other equities analysts also recently issued research reports about the company. Wells Fargo & Company lifted their price target on Cardinal Health from $95.00 to $101.00 and gave the company an “underweight” rating in a research note on Thursday. Morgan Stanley lifted their price target on Cardinal Health from $114.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday. Argus cut their price target on Cardinal Health from $120.00 to $115.00 and set a “buy” rating for the company in a research note on Wednesday, May 15th. UBS Group lifted their price target on Cardinal Health from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Robert W. Baird lifted their price target on Cardinal Health from $130.00 to $137.00 and gave the stock an “outperform” rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $113.69.
Read Our Latest Research Report on CAH
Cardinal Health Stock Performance
Cardinal Health (NYSE:CAH – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.74 by $0.10. Cardinal Health had a negative return on equity of 54.74% and a net margin of 0.25%. The firm had revenue of $59.87 billion during the quarter, compared to analyst estimates of $58.74 billion. During the same period last year, the company posted $1.55 EPS. The business’s quarterly revenue was up 12.1% on a year-over-year basis. On average, equities analysts anticipate that Cardinal Health will post 7.35 earnings per share for the current year.
Institutional Trading of Cardinal Health
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Clearstead Trust LLC purchased a new position in Cardinal Health during the fourth quarter worth about $25,000. Cultivar Capital Inc. purchased a new position in Cardinal Health during the second quarter worth about $27,000. Raleigh Capital Management Inc. grew its position in Cardinal Health by 4,466.7% during the fourth quarter. Raleigh Capital Management Inc. now owns 274 shares of the company’s stock worth $28,000 after buying an additional 268 shares in the last quarter. YHB Investment Advisors Inc. purchased a new position in Cardinal Health during the first quarter worth about $32,000. Finally, LRI Investments LLC purchased a new position in Cardinal Health during the first quarter worth about $32,000. 87.17% of the stock is currently owned by institutional investors.
Cardinal Health Company Profile
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Featured Stories
- Five stocks we like better than Cardinal Health
- Health Care Stocks Explained: Why You Might Want to Invest
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- 3 Healthcare Dividend Stocks to Buy
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- How to Calculate Options Profits
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Cardinal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardinal Health and related companies with MarketBeat.com's FREE daily email newsletter.